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Modulating the unfolded protein response to prevent neurodegeneration and enhance memory
Recent evidence has placed the unfolded protein response
(UPR) at the centre of pathological processes leading to
neurodegenerative disease. The translational repression
caused by UPR activation starves neurons of the essential
proteins they need to function and survive. Restoration of
protein synthesis, via genetic or pharmacological means, is
neuroprotective in animal models, prolonging survival.
This is of great interest due to the observation of UPR
activation in the post mortem brains of patients with Alz-
heimer’s, Parkinson’s, tauopathies and prion diseases.
Protein synthesis is also an essential step in the formation
of new memories. Restoring translation in disease or
increasing protein synthesis from basal levels has been
shown to improve memory in numerous models. As
neurodegenerative diseases often present with memory
impairments, targeting the UPR to both provide
neuroprotection and enhance memory provides an
extremely exciting novel therapeutic target.
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Introduction: the protein misfolding disorders
The development of disease-modifying therapies for
neurodegenerative diseases remains one of the biggest
challenges facing society worldwide. As life expectancy
increases, a concurrent rise in neurodegenerative dis-
eases is occurring globally as the population ages. These
disorders, which include Alzheimer’s disease (AD), Par-
kinson’s disease (PD), frontotemporal dementia (FTD)
and tauopathies, as well as amyotrophic lateral sclerosis
(ALS) and prion diseases, have distinct clinical, patho-
logical and biochemical signatures, and all involve the
accumulation of disease-specific misfolded proteins in
the brain. They are now collectively termed protein
misfolding disorders [1]. At the molecular level, abnor-
mally folded proteins include oligomers, aggregates or
large-protein inclusions. A great deal of research effort
has been directed to unraveling how each individual
‘toxic’ protein exerts its deleterious effects in specific dis-
eases, but to date, mechanistic insights into how these
cause neuronal loss has been limited and consequently
therapeutic advances have been elusive.
AD is the most common cause of dementia and is
characterized by episodic memory loss, progressive cog-
nitive impairment and behavioural changes. Pathologi-
cally, amyloid plaques and neurofibrillary tangles are
seen in post mortem brains. Amyloid plaques are mainly
composed of amyloid-β (Aβ) peptides, typically 1–40 and
1–42 amino acids in size, that are produced from the
cleavage of the amyloid precursor protein (APP) by
secretases [2]. Hyperphosphorylated tau protein misfolds
and aggregates to form neurofibrillary tangles [3]. PD is
characterized by extra-pyramidal motor symptoms and
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signs, caused by the loss of dopaminergic neurons in the
substantia nigra with variable dementia [4]. Aggregated
α-synuclein is the major component of Lewy bodies,
abnormal aggregates of protein that are characteristic of
PD [5]. ALS is a progressive paralytic disease, involving
the selective degeneration of motor neurons in the
central and peripheral nervous systems that eventually
leads to breathing failure. Several misfolded proteins
have been linked to ALS, including superoxide dismutase
1 (SOD1), TAR DNA-binding protein 43 KDa (TDP-43)
and fused in sarcoma [6]. The prototypic, but rarest, of
these disorders are the prion diseases, which include
Creutzfeldt–Jakob disease (CJD). These are characterized
clinically by rapidly progressive dementia and movement
disorders, and pathologically by spongiform degeneration
of the brain and the accumulation of protease-resistant
prion protein (PrP) [7].
It is increasingly clear that this group of diseases have
common features as well as specific characteristics. Prion
diseases are transmissible, and the mechanism of infec-
tivity and spread involves conversion of native PrP (PrPC)
by the misfolded form, termed PrPSc, via an auto-catalytic
post-translational change in conformation. As neurons
become depleted of PrPC, newly synthesized PrPC is pro-
duced, providing additional substrate for the conversion.
PrPSc can spread between neurons, gradually increasing
the area of the brain affected, or between organisms if
infected material is ingested or transferred by iatrogenic
exposure. It is now apparent that Aβ, tau and
α-synuclein are capable of the spreading templated
conformational change first described for prions. It has
been shown that this can cause spread between cells in
vitro [8–10] and also in mouse models, where spread of
these proteins can cause regional pathology and disease
progression [11–13]. Recently, the propagation of wild-
type α-synuclein causing sporadic phenotypes has been
reported, as has transmission between animals [13,14].
However, despite the universality of the prion-like
spreading phenomenon, not all of these models show
associated neurodegeneration, especially when trans-
ferred between animals [15]. Nevertheless, this raises the
concept that protein misfolding disorders have two
aspects, cell autonomous processes that cause cellular
dysfunction and neurodegeneration, and non-cell
autonomous processes through which the misfolded pro-
teins, and pathology, spreads.
Another common theme in these disorders is
endoplasmic reticulum (ER) stress [16]. The ER controls
the different cellular processes by which many proteins are
synthesized, folded, modified and transported to their
intended destinations. Disturbance in the function of the
ER leads to ER stress and is usually caused by accumula-
tion of unfolded proteins and by changes in calcium
homeostasis within the ER [17]. In neurodegenerative dis-
eases, many of the cellular processes controlled by the ER
can be disrupted by the disease pathology, causing stress
that contributes and exacerbates neuronal cell death [16].
The cell’s main weapon against ER stress is induction of
the unfolded protein response (UPR), which has recently
emerged as an extremely interesting and attractive thera-
peutic target [18], due to its role in memory and
neurodegeneration.
The UPR
The UPR is a protective cellular response induced during
periods of ER stress that aims to reduce unfolded
protein load and restore protein-folding homeostasis,
‘proteostasis’. Secreted and transmembrane proteins enter
the ER as unfolded proteins to be properly assembled or to
be targeted for degradation [19]. During ER stress, proteins
inside the ER lumen waiting to be folded and exported build
up, causing a backlog that is stressful to the cell. This is
detected by binding immunoglobulin protein (BiP), which
binds to exposed hydrophobic domains of unfolded pro-
teins [20]. The UPR has three arms (Figure 1), which initi-
ates signalling cascades through protein kinase RNA
(PKR)-like ER kinase (PERK), inositol-requiring enzyme 1
(IRE1) and activating transcription factor 6 (ATF6) [18].
BiP holds these proteins in an inactive state until it binds
unfolded proteins and dissociates, allowing their activa-
tion. The cells’ first response to ER stress is to attenuate
further protein synthesis until the unfolded protein
backlog is removed. This is controlled by PERK, which
when freed from BiP, dimerizes and autophosphorylates
[21]. Phosphorylated PERK (PERK-P) will then phosphor-
ylate eIF2α, rapidly and potently attenuating translation
[22]. eIF2α is a vital component of ternary complex, which
loads mRNA onto the ribosome during the initiation of
translation [23]. The energy for this reaction is supplied in
the form of guanosine-5′-triphosphate (GTP) by eIF2B.
Phosphorylated eIF2α (eIF2α-P) binds so tightly to eIF2B
that it can no longer recycle GTP, and due to the overabun-
dance of eIF2α compared with eIF2B, even a small increase
in eIF2α-P will greatly inhibit ternary complex formation
and hence translation [23].
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Paradoxically, the translation of some proteins is
increased after eIF2α phosphorylation, due to the presence
of multiple open reading frames in their 5′ untranslated
regions [24]. One such protein is activating transcription
factor 4 (ATF4) [25]. ATF4 controls the expression of
various genes involved in apoptosis, autophagy, amino acid
metabolism and antioxidant responses. Excessive UPR acti-
vation causes ATF4 to induce the transcription of the pro-
apoptotic C/EBP homologous protein (CHOP). There are
also three other kinases that can phosphorylate eIF2α,
each of which is activated by a different cellular
stress: the double-stranded RNA-activated protein kinase
(PKR) responds to viral infection, general control non-
derepressible-2 (GCN2) is activated during amino acid star-
vation and the heme-regulated inhibitor kinase responds
to heme deficiency. Cytoprotective signalling through these
eIF2α kinases is termed the integrated stress response [26].
After the ER stress has been resolved and any unfolded
proteins have been removed, the translational repression is
reversed by dephosphorylation of eIF2α by the phos-
phatase GADD34 [27].
The IRE1 and ATF6 arms of the UPR aim to increase the
protein folding ability of the cell via the induction of chap-
erones and facilitate the removal of terminally misfolded
proteins. Activation of IRE1 by dimerization and
autophosphorylation enables its endoribonuclease activ-
ity and catalyses the splicing of x-box binding protein 1
(XBP1) mRNA [28]. This splicing causes a frame shift,
creating a stable and potent transcription factor that
induces a plethora of genes involved in protein folding,
lipid synthesis (that increases ER volume) and transloca-
tion into the ER. Importantly, the ER-associated degrada-
tion (ERAD) pathway that helps to remove misfolded
proteins is also induced [29]. ATF6 is activated after cleav-
age by site 1 and site 2 proteases, and translocates to the
nucleus to induce the expression of XBP1, BiP, CHOP and
ATF6
eIF2α
IRE1αPERK
GCN2
P P P P
P
PKR
GSK2606414
reduced 
protein sythesis
memory impairment 
and neurodegeneration
XBP1
UPRcellular stress
upregulation of 
UPR target genes
nATF6
ATF4
CHOP
ISRIB
eIF2α
P
GADD34
salubrinal
Figure 1. UPR and ISR signalling through eIF2α-P. Unfolded proteins induce the induction of the UPR, which signals through PERK, IRE1
and ATF6. PERK phosphorylates eIF2α, leading to the rapid attenuation of protein synthesis. Chronic reduction in protein synthesis can
lead to memory impairment and neurodegeneration. eIF2α-P also leads to the selective translation of some proteins such as ATF4 and the
pro-apoptotic CHOP. Other kinases activated by cellular stress, such as PKR and GCN2, can also phosphorylate eIF2α. GADD34
dephosphorylates eIF2α-P, restoring translation to normal levels. The PERK inhibitor GSK2606414 and the compound ISRIB prevent
neurodegeneration and improve memory, respectively. Salubrinal inhibits eIF2α-P dephosphorylation, exacerbating neurodegeneration in
some, but not all models. ATF4, activating transcription factor 4; ATF6, activating transcription factor 6; eIF2α-P, phosphorylated eIF2α;
GNC2, general control non-derepressible-2; IRE1, inositol-requiring enzyme 1; ISR, integrated stress response; PERK, PKR-like endoplasmic
reticulum kinase; PKR, protein kinase RNA; UPR, unfolded protein response; XBP1, x-box binding protein 1.
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genes involved in ERAD [30]. For an in-depth discussion of
the roles of IRE1 and ATF6 in neurodegenerative disease,
see Hetz and Mollereau [16].
UPR activation in neurodegenerative disease
The UPR is central to the cell’s response to dysregulated
proteostasis. Markers of UPR activation including PERK-P
and eIF2α-P have been reported in the brains of patients
with AD, PD, ALS, the tauopathy progressive supranuclear
palsy (PSP) and prion disease [31–36]. Upregulation of
UPR markers in the brain in these disorders are temporally
and spatially associated with abnormal protein aggrega-
tion and the occurrence of neuropathological features. In
ALS, the detection of ER stress markers in body fluids has
even been suggested as a possible biomarker for disease
progression [37]. Overactivation of the PERK branch of the
UPR has recently been implicated in the pathogenesis of
PSP, a tauopathy characterized by widespread tau pathol-
ogy and progressive neurodegeneration. PERK-P and
eIF2α-P are found in the pons, medulla, midbrain and
hippocampus of post mortem patients, the regions of the
brain most affected by PSP [34]. A genome-wide associa-
tion study searching for common variants influencing the
risk of PSP found a single-nucleotide polymorphism (SNP)
in intron 2 of the PERK gene,EIF2AK3 [38]. This SNP was
found to be in linkage disequilibrium with three non-
synonymous coding variants, two in the ER luminal
protein-sensing domain and the third in the PERK kinase
domain. The functional significance of these variants
was previously investigated in lymphoblastoid cell lines
[39]. When these cells were exposed to the ER stressor
thapsigargin, they demonstrated a stronger stress
response, suggesting the high-risk variant increases the
risk of PSP via a stronger UPR activation. Animal models of
neurodegeneration also exhibit upregulation of ER stress
markers, including rTg4510 mice, which overexpress the
human tau mutation P301L associated with FTD, 5xFAD
mice that express five AD linked mutations, mutant SOD1
(mSOD1) mice and a mutant huntingtin mouse model
[40–43].
UPR in prion disease: cause and effect
in neurodegeneration
There is an obvious correlation between UPR markers and
neuropathology, but does UPR activation actively contrib-
ute to these diseases? Recently, we directly linked UPR acti-
vation to neurodegeneration in prion-diseased mice. We
used the Tg37+/− mouse model of prion disease that suc-
cumbs to Rocky Mountain Laboratory prion infection in
around 12 weeks [44–46]. Synapse loss occurs in these
mice at 7 weeks post-infection (wpi), followed by memory
loss at 8 wpi, a drastic reduction in protein synthesis and
synaptic protein levels at 9 wpi, and neuronal death at 10
wpi. Rising levels of misfolded prion protein cause sus-
tained overactivation of the PERK-eIF2α branch of the
UPR in neurons resulting in an uncompensated decline in
global translation rates, synaptic failure and neuronal
death [47]. Similar UPR activation was also observed in
wild-type mice [47].
We first tested the hypothesis that reducing eIF2α-P
would restore translation and prevent neurodegeneration
(Figure 2). Prion-infected mice were injected with
lentiviruses expressing either the eIF2α-P-specific phos-
phatase GADD34 or short hairpin RNA to reduce
PrP expression. Salubrinal, an inhibitor of eIF2α-P
dephosphorylation, was also tested to determine if it exac-
erbated disease, as this increases eIF2α-P [47].
Both GADD34 overexpression and PrP knockdown
restored global translation rates at 9 wpi. As a result, syn-
aptic protein levels, synaptic transmission and synapse
number in prion-diseased mice treated with GADD34 or
PrP knockdown were protected and equivalent to levels in
uninfected control mice. There was extensive neuronal
protection in the hippocampus, with no neuronal loss and
greatly reduced spongiform change. The burrowing
behavioural phenotype, which measures motivation and
is dependent on an intact hippocampus and pre-frontal
cortex [48,49], was also protected. Overexpression of
GADD34 and PrP knockdown also had a modest, but
highly significant, effect on survival [47].
Critically, treatment with salubrinal had the opposite
effect, by preventing dephosphorylation of eIF2α-P. Thus,
eIF2α-P levels were markedly higher at 9 wpi than in
prion-only controls, causing further repression of global
translation. Salubrinal treatment resulted in earlier severe
neuronal loss and significantly accelerated disease com-
pared with untreated prion-infected mice [47].
The striking neuroprotection achieved by genetic
manipulation of the UPR led to the prediction that phar-
macological inhibition of PERK/eIF2α-P would be simi-
larly protective. A highly selective inhibitor of PERK,
GSK2606414 [50], was tested in prion-infected mice by
oral administered from 7 wpi [51]. The PERK inhibitor
prevented the rise of eIF2α-P observed in disease
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and restored global protein synthesis rates. As with
genetic manipulation of the UPR, there was marked
neuroprotection throughout the brain and the absence of
clinical signs of disease (Figure 3). The beneficial effects
were also observed in animals treated after behavioural
signs had emerged [51]. Effects on survival could not be
assessed due to toxicity associated with the compound,
which resulted in weight loss and mild hyperglycaemia,
necessitating termination of the experiment. Critically,
the compound acts downstream, and independently, of
the primary pathogenic process of prion replication and
is effective despite continuing accumulation of PrP. We
hypothesize that the UPR is triggered by rising levels of
total PrP synthesis in the ER rather than as a direct effect
of aggregation of misfolded PrP as this occurs largely
extracellularly or within the endosomal compartment.
This stems from the observation that total PrP mRNA
levels increase during prion infection, suggesting that
increased synthesis of native PrP may cause misfolding
and UPR activation [47], and there is evidence that
overexpression of protein production can induce UPR
markers [52].
There is further evidence for a role of the UPR in prion
disease. Upregulation of several chaperones and ER stress
proteins such as BiP, GRP94 and GRP58 is observed in
patients with CJD, which is mirrored in mouse models of
prion disease [35,36]. This suggests ER stress and abnor-
mal homeostasis are features of prion disease. Disruption
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Figure 2. Manipulation of the UPR rescues protein translation and is neuroprotective in prion-diseased mice. Lentivirally delivered shRNA
against PrP (blue bar) or overexpression of GADD34 (yellow bar) reduces levels of eIF2α-P, restoring global protein synthesis rates, as
measured by 35S-methionine incorporation levels, compared with uninfected mice (white), untreated prion-diseased mice (black) or empty
vector controls (grey). Salubrinal (brown) had a detrimental effect in the same experiments. The restoration of translation provided
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PrP, protease-resistant prion protein; shRNA, short hairpin RNA; UPR, unfolded protein response; wpi, weeks post-infection.
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of calcium homeostasis, and the resulting ER stress, has
emerged as another component of the development of
prion disease. Exposing cells to purified PrPSc from the
brain of scrapie-infected mice induces ER stress and the
release of calcium from the ER. This is associated with the
upregulation of several ER chaperones, which are also
found in the brains of CJD patients [53]. Cells chronically
infected with prions are more susceptible to ER stress-
mediated cell death, linked with a stronger UPR activation
after exposure to ER stress-inducing agents such as
tunicamycin and thapsigargin [53].
GSK2606414 has also been used to ameliorate
TDP-43 toxicity in Drosophila and mammalian neuron
models of ALS [54]. These beneficial effects were again
due to the reduction of eIF2α-P levels, and these data
also demonstrate that PERK inhibition is likely to be
useful against the range of neurodegenerative disorders.
Genetic reduction of PERK has also been demonstrated
to prevent neurodegeneration and cognitive impairment
in the 5xFAD model of AD [43].
As well as the direct therapeutic interventions that
target the UPR to prevent neurodegeneration discussed
above, there is increasing evidence of the involvement of
dysregulated UPR signalling across the spectrum of
neurodegenerative disease.
UPR in AD
In AD, eIF2α-P levels correlate with elevated BACE1 (an
enzyme that cleaves APP into Aβ) levels in transgenic
mice as well as in AD patient brains [55]. A comparison
of the expression of BiP in the different Braak stages of
AD suggests UPR activation is an early event [56]. Treat-
ment of cells with Aβ peptides leads to the activation of
ER-specific caspases, which correlates with the induction
of apoptotic cell death [57]. Exposing cells to Aβ
oligomers or fibrils in different experimental models can
also trigger ER stress, which has been shown to lead to
the phosphorylation of eIF2α, PERK and other indicators
of UPR activation [58]. XBP1 controls a number of UPR-
related genes, but it has also been reported to upregulate
a number of AD-associated proteins, including CDK5,
and the γ-secretase complex, which is involved in APP
processing to Aβ [59]. ATF4 has also been shown to
regulate γ-secretases, enhancing their activity during
periods of UPR activation [60,61]. ER stress may be
inducing a positive feedback mechanism where protein
aggregation may be exacerbating the conditions that
promote the production of the misfolding protein itself.
In agreement with this, PERK knockout significantly
decreases Aβ load in the hippocampus [62]. This further
emphasizes the potential of UPR inhibition as a promis-
ing therapeutic target.
UPR activation is also associated with hyper-
phosphorylated tau. PERK-P has been observed in
neurons and glia that exhibit tau pathology, and is
upregulated during the early phase of disease [63]. In
vitro studies suggest that induction of ER stress by the
exposure of cells to Aβ oligomers correlates with the
induction of tau phosphorylation, suggesting a link
between ER stress, Aβ-mediated neurotoxicity and tau
hyperphosphorylation [64]. Induction of UPR signalling
has been shown to induce tau phosphorylation, possibly
via the activation of glycogen synthase kinase 3β (GSK-
3β) [65], demonstrating a direct link between UPR activa-
tion and neurodegenerative processes. Furthermore,
neurons displaying PERK-P coexpress active GSK-3β in
AD brains [32]. The link between metabolic stress and
UPR activation caused by tau phosphorylation has been
investigated [66]. It was found that metabolic stress
activated the UPR, which in turn led to the reversible
phosphorylation of tau. Inhibiting the UPR using
GSK2606414 and reducing cellular stress with a chemi-
cal chaperone reduced tau phosphorylation, validating
UPR inhibition in tauopathies [66]. Studies by Ma et al.
and Lourenco et al., discussed in more detail below, also
provide evidence for a direct role of the UPR in AD
[62,67].
UPR in PD
In PD, mutant α-synuclein has also been shown to accu-
mulate within the ER, directly activating the PERK arm of
the UPR by binding to BiP [68]. The accumulation of
mutant α-synuclein in dopaminergic cells increased the
expression of BiP and induced the expression of the UPR-
related transcription factor ATF4. The authors also sug-
gested that activation of the UPR pathway in cells by
mutant α-synuclein coincided with pro-apoptotic changes
[68]. The A53T missense mutation in the α-synuclein
gene causes dominant familial PD [69]. This mutation
is associated with UPR activation, as observed by an
increase in CHOP and BiP expression and increased
phosphorylation of eIF2α, suggesting the UPR is active in
these cells [70]. ER stress leads to mitochondrial dysfunc-
tion, but inhibition of caspase-12, a caspase induced
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by UPR activation, protected the A53T α-synuclein-
overexpressing cells from cell death, suggesting that the
activated UPR was inducing apoptosis [70].
UPR in ALS
Approximately 2% of ALS patients have a mutation in the
SOD1 gene and transgenic rodents expressing the mSOD1
are the most commonly used model of study in ALS
research [71]. mSOD1 misfolds, aggregates and induces
the UPR in transgenic mSOD1 mice, causing apoptosis
and has been implicated in the development of ALS [72].
The levels of the ER chaperone, protein disulphide
isomerase (PDI) in particular, were increased and were
shown to co-localize with aggregated mSOD1 protein. In a
study using mSOD1 mouse models of ALS, vulnerable
motor neurons were shown to be selectively prone to
axonal degeneration in cells that demonstrated a UPR
response. This could be attenuated or exacerbated by
treatment protecting against or stimulating further ER
stress, respectively [40]. Insufficient ERAD of misfolded
proteins is associated with a range of neurodegenerative
conditions, including ALS. The dysfunction of ERAD,
causing ER stress, has been shown to occur in mSOD1-
containing motor neurons, through a mechanism involv-
ing Derilin-1, an ERAD-linked protein, subsequent ER
stress-induced activation of the ASK1 pathway and ulti-
mately apoptosis [73]. This was found to be caused by the
interaction between Derilin-1 and mSOD1, which caused
dysregulation of ERAD leading to ER stress-induced ASK1
activation, apoptosis and disease progression.
ER stress or other processes? Conflicting
evidence involving the UPR
Although the UPR is normally a protective cellular
response, the data presented above demonstrate that
its dysregulation has a central role in many diseases.
Chronic UPR activation, and the resulting swith from
cytoprotective to cytotoxic signalling, contributes to
disease. There are a number of unresolved questions,
including: Why does the UPR become chronically acti-
vated and what causes the switch to cytotoxic signalling?
If the majority of the disease-modifying proteins discussed
above do not build up in the ER lumen, why is the UPR
activated? Is ER stress a response to neurodegeneration or
does it contribute to disease initiation?
These questions are now beginning to be answered. In
most cases, it is likely that the induction of ER stress in
neurodegenerative disease is not caused by misfolded
protein build up in the ER lumen. However, some examples
exist where disease-associated misfolded proteins do build
up in the ER. mSOD1 can translocate into the ER and has
been observed bound to BiP and the foldase PDI [72].
Mutant α-synuclein oligomers have also been found inside
the ER in animal models as well as human tissue samples,
again in association with BiP [68,74]. These misfolded
proteins may be sequestering essential ER proteins such as
BiP, triggering ER stress. Interestingly, in mSOD1 and
mutant α-synuclein models of neurodegeneration, treat-
ment with salubrinal (hence increasing eIF2α-P levels) is
protective, in contrast to prion disease where salubrinal
exacerbates disease 4 [40,75]. When mSOD1 and mutant
α-synuclein aggregate in the ER, they are triggering a
form of ‘pure’ ER stress that the UPR is designed to
combat, so it is no surprise that augmenting UPR activity
with salubrinal is neuroprotective. However, in other dis-
eases such as AD, the tauopathies and prion disease,
where misfolded protein aggregation is mainly cytoplas-
mic or extracellular, there is a more general nonspecific
proteostatic dysregulation, hence relief of ER stress itself
is less relevant than restoring protein synthesis. It is here
that chronic UPR activation becomes detrimental to the
cell and UPR inhibition is a viable therapeutic target. This
leads to the hypothesis that the secondary effects of
translational shutdown is the lethal process driving
neurodegeneration in these cases, hence why reducing
eIF2α-P levels is neuroprotective.
As discussed above, it is possible that the increased
transcription of PrP, rather than the buildup of misfolded
PrPSc itself, is a cause of the ER stress in prion disease.
Further investigations are also uncovering mechanisms
of UPR activation caused by other misfolded proteins
that do not build up in the ER. Abisambra et al. investi-
gated how tau can activate the UPR using the tg4510
mouse model and an inducible tau cell model [41]. They
found increasing PERK-P as the disease progressed,
which was preceded by an increase in ubiquitin. ERAD
tags unfolded proteins with ubiquitin, which targets
them for degradation by the proteasome. Removing tau
caused the levels of PERK-P and ubiquitin to lower. Tau
was found to co-immunoprecipitate with components of
the ERAD system that export misfolded proteins from the
ER, and proteins that are normally efficiently removed by
ERAD built up in the hippocampus of tau positive mice.
The authors conclude that tau was able to impair ERAD
directly, leading to UPR stress and the associated cell
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death that occurs when this pathway is activated.
Mutant huntingtin, the misfolded protein associated with
Huntington’s disease, has also been shown to cause
stress via the blocking of the ERAD pathway [76].
However, the precise molecular steps between ERAD dis-
ruption and subsequent eIF2α phosphorylation are
unclear.
Memory: another key role for protein synthesis
Protein synthesis is also central to memory formation,
particularly via eIF2α modulation. This is important in
this context, as memory loss is very often a central feature
of neurodegenerative disease, especially in dementia.
Neurophysiologically, memories are usually divided into
short-term memory, typically classed as lasting only a few
hours in duration, and long-term memory, lasting for
years or even the lifespan of the organism, but there is no
absolute distinction between memory types [77]. Long-
term memories require de novo protein synthesis [78], but
there are no definitive time frames that differentiate
protein synthesis-dependent and protein synthesis-
independent memories. Memory is often described as an
activity-dependent change in the strength and/or number
of synaptic connections that underpin long-term changes
in neural circuits with a possible adaption in behaviour
[79]. The hippocampus and the amygdala are the two
most important structures in the brain involved in
memory. Widely studied correlates of memory are long-
term potentiation (LTP) and long-term depression as they
share similar molecular and cellular mechanisms [80].
Longer lived forms of LTP also require protein synthesis
[81]. Conversely, protein synthesis inhibitors have repeat-
edly been shown to inhibit memory formation and con-
solidation in multiple behavioural models [82]. The use or
retrieval of an established memory also results in a second
phase of increased protein synthesis, a process referred to
as memory reconsolidation [83].
So how is the UPR involved in memory formation and
consolidation? The translational attenuation of protein
synthesis after eIF2α phosphorylation will prevent many
of the proteins required from being produced during
periods of ER stress that are required for LTP and long-
term memory formation. Although dendrites have a pool
of mRNA and translational machinery at the synapse, this
is not resistant to eIF2α-P, and any longer term memory
consolidation or reconsolidation will require de novo
protein synthesis. Significantly, ATF4 is a repressor of
cAMP response element-binding protein (CREB)-mediated
gene expression, which is essential for long-lasting
changes in synaptic plasticity and memory [84]. Conse-
quently, eIF2α phosphorylation impinges on two central
processes that are crucial for the formation and storage of
long-term memories: new protein synthesis and CREB-
mediated gene expression (Figure 4). In agreement with
this, stimuli that produce increases in synaptic strength,
such as tetanic stimulation, brain-derived neurotrophic
factor or cAMP activators, decrease the phosphorylation
of eIF2α [85,86]. In a fear conditioning test that directly
induces protein synthesis-dependent memory, eIF2α-P is
also reduced, leading the authors to conclude that eIF2α
regulates the switch from short- to long-term synaptic
plasticity and memory [87].
Modulating the UPR to enhance memory
Protein synthesis is therefore an essential part of memory
storage, and the UPR tightly regulates protein synthesis
rates, especially during periods of stress. This presents the
question: can modulating the UPR enhance memory?
Genetic reduction of eIF2α-P in hippocampal slices from
mice, either lacking GCN2 or heterozygous for a mutated
eIF2α that cannot be phosphorylated, reduced the thresh-
old for the induction of both LTP and learning in several
behavioral tests [85,87]. Conversely, preventing eIF2α
dephosphorylation with the small molecule Sal003 blocks
both LTP and long-term memory formation. The impair-
ment of LTP by Sal003 is mediated by ATF4, as LTP
induced in hippocampal slices from ATF4 knockout mice
is resistant to Sal003 [87]. Exacerbated phosphorylation
of eIF2α was also observed to induce cognitive impair-
ment [88]. In agreement with these findings, a study dem-
onstrated that genetic deletion of two of the eIF2α
kinases, PERK and GCN2, improves cognitive function and
synaptic plasticity [62]. PKR, another eIF2α kinase, has
also been deleted, which was also shown to increase learn-
ing and memory [89].
Several recent studies have explored the link between
UPR activation, memory and neurodegeneration.
Lourenco et al. demonstrated that brain inflammation in
AD models engages PKR to induce synaptic loss and
memory impairments [67]. The authors also demon-
strated that Aβ oligomers alter insulin signalling leading
to memory deficits through a mechanism involving the
pro-inflammatory cytokine tumor necrosis factor-α. After
investigating the effects of PERK and GCN2 knockout, Ma
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et al. also demonstrated that these deletions can protect
against memory impairment and neurodegeneration in
AD model mice [62]. Genetic deletion of PERK and
administration of a small molecule PERK inhibitor
improved memory deficits as well as offering substantial
neuroprotection [43,51]. Importantly, these reports dem-
onstrate that despite reducing the activity of one branch
of the UPR, genetic or pharmacological manipulation
improved cognitive aspects of neurodegenerative disease
without affecting the ability of the neurons to survive the
stress of misfolded protein aggregation.
It is unclear if the improvements in memory after UPR
inhibition in these disease models are due to the release of
translational repression that was preventing memory for-
mation, or a consequence of the neuroprotection con-
ferred. However, it is possible to improve memory using
small molecules targeting downstream UPR signalling.
An interesting study identified a small molecule, ISRIB,
that inhibits downstream signalling of eIF2α-P [90].
ISRIB improves memory in mice and rats in a number of
behavioural tests, without directly lowering eIF2α-P
levels. However, it effectively makes cells insensitive to
eIF2α–P, lowering ATF4 expression. The authors conclude
that memory consolidation is inherently inhibited by
eIF2α phosphorylation, and compounds such as ISRIB
can release cells from this tonic inhibition.
Conclusions
The UPR is the focus of increasing interest as an attractive
target for disease-modifying novel therapies due to its
emerging role in the pathogenesis of neurodegenerative
disease. The fact that these therapies are likely to increase
memory in patients, where memory loss is a major
problem, further improves the attractiveness of the UPR as
a target. It remains to be seen if the problems associated
with PERK inhibition can be abrogated. This, and other
agents that mimic the action of ISRIB, for example, might
hold the key to the first truly disease-modifying and non-
specific treatment for neurodegeneration. Further work is
needed to elucidate the exact nature of how these
misfolded proteins cause ER stress and UPR activation,
and the conditions that push UPR activation from a ben-
eficial protective response to a central tenet of disease
pathogenesis. UPR activation may also provide a useful
biomarker for neurodegenerative disease.
In conclusion, it is becoming increasingly clear that
the translational repression due to phosphorylation of
eIF2α is a key link between neuropathology and memory
impairment in neurodegenerative disease. The reports
discussed in this review suggest that restoration of
protein synthesis through the eIF2α pathway is an
attractive target to reduce memory impairment and
learning stimulus/ 
neurotransmission
short-term memory transcription translation long-term memory
consolidation
UPR/ISR activation
eIF2α P
ATF4
CREB
Figure 4. The role of the UPR in long-term memory formation. A learning stimulus leads to short-term memory formation. The process of
consolidation, which requires transcription and translation, cements short-term memories into long-term memories. The UPR can inhibit
this process via eIF2α-P-mediated translational repression and inhibition of the transcription factor CREB by ATF4. ATF4, activating
transcription factor 4; CREB, cAMP response element-binding protein; eIF2α-P, phosphorylated eIF2α; ISR, integrated stress response; UPR,
unfolded protein response.
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prevent neurodegeneration across the spectrum of these
disorders.
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